Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 18/20 | 0.49 |
| ▸ | CNR1 | P21554 | 16/20 | 0.49 |
| ▸ | GPR18 | Q14330 | 3/20 | 0.47 |
| ▸ | GPR55 | Q9Y2T6 | 3/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29627394 | 0.85 | CNR2 (0.52) | CNR2CNR1GPR55 | |
| SCHEMBL24539687 | 0.77 | CNR1 (0.49) | CNR2CNR1GPR18GPR55 | |
| SCHEMBL24539603 | 0.70 | MEN1 (0.49) | CNR2CNR1GPR18GPR55 | |
| SCHEMBL29627416 | 0.70 | MEN1 (0.49) | CNR2CNR1GPR18GPR55 | |
| SCHEMBL4884009 | 0.70 | CNR1 (0.76) | CNR2CNR1 | |
| SCHEMBL1129199 | 0.70 | CNR1 (0.58) | CNR2CNR1 | |
| SCHEMBL6506230 | 0.69 | CNR2 (0.57) | CNR2CNR1 | |
| SCHEMBL10938957 | 0.69 | CNR2 (0.57) | CNR2CNR1 | |
| SCHEMBL6652267 | 0.69 | CNR2 (0.57) | CNR2CNR1 | |
| SCHEMBL507786 | 0.69 | CNR2 (0.57) | CNR2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12612358-B2 | Resorcinol-based compounds and uses thereof | SUTTER BAY HOSPITALS (US) | 2026-04-28 | — | — | US | disclosed |
| US-20240059646-A1 | RESORCINOL-BASED COMPOUNDS AND USES THEREOF | ORGANIX INC. | 2024-02-22 | — | — | US | disclosed |
| WO-2022133058-A1 | RESORCINOL-BASED COMPOUNDS AND USES THEREOF | SUTTER BAY HOSPITALS (US) | 2022-06-23 | — | — | WO | disclosed |
| WO-2022133058-A1 | RESORCINOL-BASED COMPOUNDS AND USES THEREOF | SUTTER BAY HOSPITALS (US) | 2022-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12612358-B2 | Resorcinol-based compounds and uses thereof | CARM1, MALT1, RCOR1 | CNR2 397/4885CNR1 115/4885GPR18 1273/4885 |
| US-20240059646-A1 | RESORCINOL-BASED COMPOUNDS AND USES THEREOF | VHL, NQO1, HRAS | CNR2 3315/4885CNR1 3278/4885GPR18 2107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.